11. T O R E ~ R E N E W ~ R E S H A P E ~ R E S T O R E ~ R E N E W
Developed for efficacy, designed for safety
Favorable composition of PLA provides
long-lasting results
• Microparticles are gradually broken down
and eliminated by normal metabolic pathways
• Slow resorption due to high molecular weight
and crystalline structure
New-Fill®—stable reconstitution for effective
administration
• Held within a well-tested emulsifying
and thickening agent
• Injected deep intradermally or
subcutaneously through
a 26 G needle1
• Requires no skin test2
Reshape
Restore
Renew
12. I n t h e t re a t m e n t o f
relapsed ovarian and relapsed small cell lung cancer*…
A first choice
for a
second chance†
*Hycamtin is indicated for the treatment of metastatic carcinoma of the ovary after failure
of initial or subsequent chemotherapy, and for small cell lung cancer sensitive disease
after failure of first-line chemotherapy. In clinical studies submitted to support approval,
sensitive disease was defined as disease responding to chemotherapy but subsequently
progressing ≥60 days (in the phase 3 study) or ≥90 days (in phase 2 studies) after
chemotherapy. †Hycamtin, as a single agent, is the most frequently prescribed second-line
agent for ovarian and small cell lung cancer (Tandem Cancer Audit, MAT 6/01).
Hycamtin is contraindicated in patients with a history of hypersensitivity to topotecan
or to any of its ingredients. Hycamtin should not be used in patients who are pregnant,
breast-feeding or those with severe bone marrow depression. The most common
serious adverse event is myelosuppression.
Please see following page for brief summary of prescribing information, including
warnings, precautions and adverse events.
